Hyaluronan in Human Tumors: Importance of Stromal and Cancer Cell-Associated Hyaluronan

Hyaluronan in Cancer Biology

Volumn , Issue , 2009, Pages 257-284

  Tammi, Raija H ^a   Kultti, Anne H ^a   Kosma, Veli Matti ^a,b   Pirinen, Risto ^a,b   Auvinen, Päivi ^b   Tammi, Markku I ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864304808     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012374178-3.10014-6     Document Type: Chapter

References (127)

1. Aaltomaa S., Lipponen P., Tammi R., et al. Strong stromal hyaluronan expression is associated with PSA recurrence in local prostate cancer. Urol Int 2002, 69:266-272.
2. Adamia S., Reiman T., Crainie M., et al. Intronic splicing of hyaluronan synthase 1 (HAS-1): a biologically relevant indicator of poor outcome in multiple myeloma. Blood 2005, 105:4836-4844.
3. Afify A.M., Craig S., Paulino A.F., Stern R. Expression of hyaluronic acid and its receptors, CD44s and CD44v6, in normal, hyperplastic, and neoplastic endometrium. Ann Diagn Pathol 2005, 9:312-318.
4. Ågren U.M., Tammi R.H., Tammi M.I. Reactive oxygen species contribute to epidermal hyaluronan catabolism in human skin organ culture. Free Radic Biol Med 1997, 23:996-1001.
5. Anggiansah C.L., Scott D., Poli A., et al. Regulation of hyaluronan secretion into rabbit synovial joints in vivo by protein kinase C. J Physiol 2003, 550:631-640.
6. Anttila M.A., Tammi R.H., Tammi M.I., et al. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res 2000, 60:150-155.
7. Auvinen P., Tammi R., Parkkinen J., et al. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 2000, 156:529-536.
8. Auvinen P.K., Parkkinen J.J., Johansson R.T., et al. Expression of hyaluronan in benign and malignant breast lesions. Int J Cancer 1997, 74:477-481.
9. Bakkers J., Kramer C., Pothof J., et al. HAS-2 is required upstream of Rac1 to govern dorsal migration of lateral cells during zebrafish gastrulation. Development 2004, 131:525-537.
10. Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 2006, 16:38-52.
11. Bertrand P., Girard N., Delpech B., et al. Hyaluronan (hyaluronic acid) and hyaluronectin in the extracellular matrix of human breast carcinomas: comparison between invasive and non-invasive areas. Int J Cancer 1992, 52:1-6.
12. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337.
13. Böhm J., Niskanen L., Tammi R., et al. Hyaluronan expression in differentiated thyroid carcinoma. J Pathol 2002, 196:180-185.
14. Calabro A., Oken M.M., Hascall V.C., Masellis A.M. Characterization of hyaluronan synthase expression and hyaluronan synthesis in bone marrow mesenchymal progenitor cells: predominant expression of HAS-1 mRNA and up-regulated hyaluronan synthesis in bone marrow cells derived from multiple myeloma patients. Blood 2002, 100:2578-2585.
15. Camenisch T.D., Spicer A.P., Brehm-Gibson T., et al. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J Clin Invest 2000, 106:349-360.
16. Christopoulos T.A., Papageorgakopoulou N., Theocharis D.A., et al. Hyaluronidase and CD44 hyaluronan receptor expression in squamous cell laryngeal carcinoma. Biochim Biophys Acta 2006, 1760:1039-1045.
17. Day A.J., de la Motte C.A. Hyaluronan cross-linking: a protective mechanism in inflammation?. Trends Immunol 2005, 26:637-643.
18. de la Motte C.A., Hascall V.C., Drazba J., et al. Mononuclear leukocytes bind to specific hyaluronan structures on colon mucosal smooth muscle cells treated with polyinosinic acid, polycytidylic acid: inter-alpha-trypsin inhibitor is crucial to structure and function. Am J Pathol 2003, 163:121-133.
19. de la Torre M., Wells A.F., Bergh J., Lindgren A. Localization of hyaluronan in normal breast tissue, radial scar, and tubular breast carcinoma. Hum Pathol 1993, 24:1294-1297.
20. del Fresno C., Otero K., Gomez-Garcia L., et al. Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J Immunol 2005, 174:3032-3040.
21. Dick S.J., Macchi B., Papazoglou S., et al. Lymphoid cell-glioma cell interaction enhances cell coat production by human gliomas: novel suppressor mechanism. Science 1983, 220:739-742.
22. Ekici S., Cerwinka W.H., Duncan R., et al. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int J Cancer 2004, 112:121-129.
23. Franzmann E.J., Schroeder G.L., Goodwin W.J., et al. Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL-1) in head and neck tumors. Int J Cancer 2003, 106:438-445.
24. Fraser J.R., Laurent T.C., Laurent U.B. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med 1997, 242:27-33.
25. Fülop C., Salustri A., Hascall V.C. Coding sequence of a hyaluronan synthase homologue expressed during expansion of the mouse cumulus-oocyte complex. Arch Biochem Biophys 1997, 337:261-266.
26. Garcia I., Vizoso F., Suarez C., et al. Relationship of tumoral hyaluronic acid and cathepsin D contents with histological type of gastric carcinoma. Int J Biol Markers 2000, 15:215-218.
27. Ghatak S., Misra S., Toole B.P. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem 2002, 277:38013-38020.
28. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001, 131(11 Suppl):3109S-3120S.
29. Glick A.B. TGFbeta1, back to the future: revisiting its role as a transforming growth factor. Cancer Biol Ther 2004, 3:276-283.
30. Hardingham T.E., Muir H. The specific interaction of hyaluronic acid with cartilage proteoglycans. Biochim Biophys Acta 1972, 279:401-405.
31. Harris E.N., Weigel J.A., Weigel P.H. Endocytic function, glycosaminoglycan specificity, and antibody sensitivity of the recombinant human 190-kDa hyaluronan receptor for endocytosis (HARE). J Biol Chem 2004, 279:36201-36209.
32. Hautmann S.H., Lokeshwar V.B., Schroeder G.L., et al. Elevated tissue expression of hyaluronic acid and hyaluronidase validates the HA-HAase urine test for bladder cancer. J Urol 2001, 165:2068-2074.
33. Hiltunen E.L., Anttila M., Kultti A., et al. Elevated hyaluronan concentration without hyaluronidase activation in malignant epithelial ovarian tumors. Cancer Res 2002, 62:6410-6413.
34. Hirvikoski P., Tammi R., Kumpulainen E., et al. Irregular expression of hyaluronan and its CD44 receptor is associated with metastatic phenotype in laryngeal squamous cell carcinoma. Virchows Arch 1999, 434:37-44.
35. Iozzo R.V. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 1998, 67:609-652.
36. Itano N., Sawai T., Atsumi F., et al. Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation. J Biol Chem 2004, 279:18679-18687.
37. Itano N., Sawai T., Miyaishi O., Kimata K. Relationship between hyaluronan production and metastatic potential of mouse mammary carcinoma cells. Cancer Res 1999, 59:2499-2504.
38. Ito M., Ito G., Kondo M., et al. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer. Cancer Lett 2005, 225:131-139.
39. Jacobson A., Brinck J., Briskin M.J., Spicer A.P., Heldin P. Expression of human hyaluronan synthases in response to external stimuli. Biochem J 2000, 348:29-35.
40. Jacobson A., Rahmanian M., Rubin K., Heldin P. Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors. Int J Cancer 2002, 102:212-219.
41. Jokela T.A., Lindgren A., Rilla K., et al. Induction of hyaluronan cables and monocyte adherence in epidermal keratinocytes. Connect Tissue Res 2008, 49:115-119. 2008.
42. Kakizaki I., Kojima K., Takagaki K., et al. A novel mechanism for the inhibition of hyaluronan biosynthesis by 4-methylumbelliferone. J Biol Chem 2004, 279:33281-33289.
43. Kanomata N., Yokose T., Kamijo T., et al. Hyaluronan synthase expression in pleural malignant mesotheliomas. Virchows Arch 2005, 446:246-250.
44. Karjalainen J.M., Tammi R.H., Tammi M.I., et al. Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma. Am J Pathol 2000, 157:957-965.
45. Karvinen S., Kosma V.M., Tammi M.I., Tammi R. Hyaluronan, CD44 and versican in epidermal keratinocyte tumours. Br J Dermatol 2003, 148:86-94.
46. Karvinen S., Pasonen-Seppänen S., Hyttinen J.M.T., et al. Keratinocyte growth factor stimulates migration and hyaluronan synthesis in the epidermis by activation of keratinocyte hyaluronan synthases 2 and 3. J Biol Chem 2003, 278:49495-49504.
47. Kemppainen T., Tammi R., Tammi M., et al. Elevated expression of hyaluronan and its CD44 receptor in the duodenal mucosa of coeliac patients. Histopathology 2005, 46:64-72.
48. Kimata K., Honma Y., Okayama M., et al. Increased synthesis of hyaluronic acid by mouse mammary carcinoma cell variants with high metastatic potential. Cancer Res 1983, 43:1347-1354.
49. Knudson C.B., Toole B.P. Fluorescent morphological probe for hyaluronate. J Cell Biol 1985, 100:1753-1758.
50. Knudson W., Toole B.P. Membrane association of the hyaluronate stimulatory factor from LX-1 human lung carcinoma cells. J Cell Biochem 1988, 38:165-177.
51. Knudson W., Biswas C., Li X.Q., Nemec R.E., Toole B.P. The role and regulation of tumour-associated hyaluronan. Ciba Found Symp 1989, 143:150-159.
52. Knudson W., Chow G., Knudson C.B. CD44-mediated uptake and degradation of hyaluronan. Matrix Biol 2002, 21:15-23.
53. Köbel M., Weichert W., Cruwell K., et al. Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcinomas and linked to patient prognosis. Virchows Arch 2004, 445:456-464.
54. Kosaki R., Watanabe K., Yamaguchi Y. Overproduction of hyaluronan by expression of the hyaluronan synthase HAS-2 enhances anchorage-independent growth and tumorigenicity. Cancer Res 1999, 59:1141-1145.
55. Kosunen A., Ropponen K., Kellokoski J., et al. Reduced expression of hyaluronan is a strong indicator of poor survival in oral squamous cell carcinoma. Oral Oncol 2004, 40:257-263.
56. Kultti A., Rilla K., Tiihonen R., et al. Hyaluronan synthesis induces microvillus-like cell surface protrusions. J Biol Chem 2006, 281:15821-15828.
57. Kwabi-Addo B., Ozen M., Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004, 11:709-724.
58. Lipponen P., Aaltomaa S., Tammi R., et al. High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer. Eur J Cancer 2001, 37:849-856.
59. Liu N., Gao F., Han Z., et al. Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells. Cancer Res 2001, 61:5207-5214.
60. Llaneza A., Vizoso F., Rodriguez J.C., et al. Hyaluronic acid as prognostic marker in resectable colorectal cancer 2000, 871690-871696.
61. Lokeshwar V.B., Schroeder G.L., Selzer M.G., et al. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer 2002, 95:61-72.
62. Lokeshwar V.B., Cerwinka W.H., Isoyama T., Lokeshwar B.L. HYAL-1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res 2005, 65:7782-7789.
63. Lokeshwar V.B., Rubinowicz D., Schroeder G.L., et al. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL-1 hyaluronidase in prostate cancer. J Biol Chem 2001, 276:11922-11932.
64. Milner M., Higman V.A., Day A.J. a pluripotent inflammatory mediator?. Biochem Soc Trans 2006, 34:446-450.
65. Misra S., Ghatak S., Toole B.P. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem 2005, 280:20310-20315.
66. Misra S., Toole B.P., Ghatak S. Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J Biol Chem 2006, 281:34936-34941.
67. Mueller M.M. Inflammation in epithelial skin tumours: old stories and new ideas. Eur J Cancer 2006, 42:735-744.
68. Mueller M.M., Fusenig N.E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004, 4:839-849.
69. Mytar B., Woloszyn M., Szatanek R., et al. Tumor cell-induced deactivation of human monocytes. J Leukoc Biol 2003, 74(6):1094-1101.
70. Nakamura H., Suenaga N., Taniwaki K., et al. Constitutive and induced CD44 shedding by ADAM-like proteases and membrane-type 1 matrix metalloproteinase. Cancer Res 2004, 64:876-882.
71. Nakazawa H., Yoshihara S., Kudo D., et al. 4-methylumbelliferone, a hyaluronan synthase suppressor, enhances the anticancer activity of gemcitabine in human pancreatic cancer cells. Cancer Chemother Pharmacol 2006, 57:165-170.
72. Normanno N., De Luca A., Bianco C., et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 366(1):2-16.
73. Nykopp, T. K., Sironen, R., Tammi, M. I., Tammi, R. H., Hämäläinen, K., Heikkinen, A.-M., Komulainen, M., Kosma, V.-M., and Anttila, M.: Increased accumulation of hyaluronan in serous ovarian carcinoma correlates with decreased expression of HYAL 1 hyaluronidase. Submitted for publication.
74. Pasonen-Seppänen S., Karvinen S., Törrönen K., et al. EGF up-regulates, whereas TGF-beta downregulates, the hyaluronan synthases HAS-2 and HAS-3 in organotypic keratinocyte cultures: correlations with epidermal proliferation and differentiation. J Invest Dermatol 2003, 120:1038-1044.
75. Petersen O.W., Nielsen H.L., Gudjonsson T., et al. Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am J Pathol 2003, 162:391-402.
76. Pienimäki J.P., Rilla K., Fülop C., et al. Epidermal growth factor activates hyaluronan synthase 2 in epidermal keratinocytes and increases pericellular and intracellular hyaluronan. J Biol Chem 2001, 276:20428-20435.
77. Pietras K., Sjöblom T., Rubin K., Heldin C.H., Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 2003, 3:439-443.
78. Pirinen R., Hirvikoski P., Böhm J., et al. Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma. Hum Pathol 2000, 31:1088-1095.
79. Pirinen R., Tammi R., Tammi M., et al. Prognostic value of hyaluronan expression in non-small-cell lung cancer: increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma. Int J Cancer 2001, 95:12-17.
80. Pirinen R.T., Tammi R.H., Tammi M.I., et al. Expression of hyaluronan in normal and dysplastic bronchial epithelium and in squamous cell carcinoma of the lung. Int J Cancer 1998, 79:251-255.
81. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4:71-78.
82. Ponting J., Kumar S., Pye D. Co-localization of hyaluronan and hyaluronectin in normal and neoplastic breast tissues. Int J Oncol 1993, 2:889-893.
83. Posey J.T., Soloway M.S., Ekici S., et al. Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL-1) for prostate cancer. Cancer Res 2003, 63:2638-2644.
84. Rilla K., Pasonen-Seppänen S., Rieppo J., Tammi M., Tammi R. The hyaluronan synthesis inhibitor 4-methylumbelliferone prevents keratinocyte activation and epidermal hyperproliferation induced by epidermal growth factor. J Invest Dermatol 2004, 123:708-714.
85. Rilla K., Siiskonen H., Spicer A.P., et al. Plasma membrane residence of hyaluronan synthase is coupled to its enzymatic activity. J Biol Chem 2005, 280:31890-31897.
86. Rilla K., Tiihonen R., Kultti A., et al. Pericellular hyaluronan coat visualized in live cells with a fluorescent probe is scaffolded by plasma membrane protrusions. J Histochem Cytochem 2008, 56:901-910.
87. Ripellino J.A., Klinger M.M., Margolis R.U., Margolis R.K. The hyaluronic acid binding region as a specific probe for the localization of hyaluronic acid in tissue sections. Application to chick embryo and rat brain. J Histochem Cytochem 1985, 33:1060-1066.
88. Rooney P., Kumar S., Ponting J., Wang M. The role of hyaluronan in tumour neovascularization (review). Int J Cancer 1995, 60:632-636.
89. Ropponen K., Tammi M., Parkkinen J., et al. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 1998, 58:342-347.
90. Saavalainen K., Pasonen-Seppänen S., Dunlop T.W., et al. The human hyaluronan synthase 2 gene is a primary retinoic acid and epidermal growth factor responding gene. J Biol Chem 2005, 280:14636-14644.
91. Setälä L.P., Tammi M.I., Tammi R.H., et al. Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate. Br J Cancer 1999, 79:1133-1138.
92. Shaw R.J., Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441:424-430.
93. Simpson M.A., Wilson C.M., Furcht L.T., et al. Manipulation of hyaluronan synthase expression in prostate adenocarcinoma cells alters pericellular matrix retention and adhesion to bone marrow endothelial cells. J Biol Chem 2002, 277:10050-10057.
94. Smola H., Thiekotter G., Fusenig N.E. Mutual induction of growth factor gene expression by epidermal-dermal cell interaction. J Cell Biol 1993, 122:417-429.
95. Stern R. Hyaluronan metabolism: a major paradox in cancer biology. Pathol Biol (Paris) 2005, 53:372-382.
96. Stern R., Jedrzejas M.J. Hyaluronidases: their genomics, structures, and mechanisms of action. Chem Rev 2006, 106:818-839.
97. Suwiwat S., Ricciardelli C., Tammi R., et al. Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 2004, 10:2491-2498.
98. Takahashi Y., Li L., Kamiryo M., et al. Hyaluronan fragments induce endothelial cell differentiation in a CD44-and CXCL1/GRO1-dependent manner. J Biol Chem 2005, 280:24195-24204.
99. Tammi R., Pasonen-Seppänen S., Kolehmainen E., Tammi M. Hyaluronan synthase induction and hyaluronan accumulation in mouse epidermis following skin injury. J Invest Dermatol 2005, 124:898-905.
100. Tammi R., Rilla K., Pienimäki J.P., et al. Hyaluronan enters keratinocytes by a novel endocytic route for catabolism. J Biol Chem 2001, 276:35111-35122.
101. Tammi R.H., Tammi M.I. Hyaluronan in epidermis and other epithelial tissues. Chemistry and Biology of Hyaluronan 2004, 395-407. Elsevier, Kidlington. H.G. Garg, C.A. Hales (Eds.).
102. Teder P., Vandivier R.W., Jiang D., et al. Resolution of lung inflammation by CD44. Science 2002, 296:155-158.
103. Theocharis A.D., Vynios D.H., Papageorgakopoulou N., Skandalis S.S., Theocharis D.A. Altered content composition and structure of glycosaminoglycans and proteoglycans in gastric carcinoma. Int J Biochem Cell Biol 2003, 35:376-390.
104. Thomas G.J., Speight P.M. Cell adhesion molecules and oral cancer. Crit Rev Oral Biol Med 2001, 12:479-498.
105. Thorne R.F., Legg J.W., Isacke C.M. The role of the CD44 transmembrane and cytoplasmic domains in co-ordinating adhesive and signalling events. J Cell Sci 2004, 117:373-380.
106. Toole B.P. Hyaluronan in morphogenesis. J Intern Med 1997, 242:35-40.
107. Tsan M.F. Toll-like receptors, inflammation and cancer. Semin Cancer Biol 2006, 16:32-37.
108. Tsuchiya N., Kondo Y., Takahashi A., et al. Mapping and gene expression profile of the minimally overrepresented 8q24 region in prostate cancer. Am J Pathol 2002, 160:1799-1806.
109. Tuhkanen H., Anttila M., Kosma V.M., et al. Genetic alterations in the peritumoral stromal cells of malignant and borderline epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3p. Int J Cancer 2004, 109:247-252.
110. Udabage L., Brownlee G.R., Waltham M., et al. Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. Cancer Res 2005, 65:6139-6150.
111. van Muijen G.N., Danen E.H., Veerkamp J.H., et al. Glycoconjugate profile and CD44 expression in human melanoma cell lines with different metastatic capacity. Int J Cancer 1995, 61:241-248.
112. Vigetti D., Ori M., Viola M., et al. Molecular cloning and characterization of UDP-glucose dehydrogenase from the amphibian Xenopus laevis and its involvement in hyaluronam synthesis. J Biol Chem. 2006, 281:8254-8263.
113. Vizoso F.J., del Casar J.M., Corte M.D., et al. Significance of cytosolic hyaluronan levels in gastric cancer. Eur J Surg Oncol 2004, 30:318-324.
114. Voutilainen K., Anttila M., Sillanpää S., et al. Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic factors and prognosis. Int J Cancer 2003, 107:359-364.
115. Wang A., Hascall V.C. Hyaluronan structures synthesized by rat mesangial cells in response to hyperglycemia induce monocyte adhesion. J Biol Chem 2004, 279:10279-10285.
116. Wang C., Tammi M., Guo H., Tammi R. Hyaluronan distribution in the normal epithelium of esophagus, stomach, and colon and their cancers. Am J Pathol 1996, 148:1861-1869.
117. Weigel P.H., Hascall V.C., Tammi M. Hyaluronan synthases. J Biol Chem 1997, 272:13997-14000.
118. Wein R.O., McGary C.T., Doerr T.D., et al. Hyaluronan and its receptors in mucoepidermoid carcinoma. Head Neck 2006, 28:176-181.
119. Wernicke M., Pineiro L.C., Caramutti D., et al. Breast cancer stromal myxoid changes are associated with tumor invasion and metastasis: a central role for hyaluronan. Mod Pathol 2003, 16:99-107.
120. Wilkinson T.S., Bressler S.L., Evanko S.P., Braun K.R., Wight T.N. Overexpression of hyaluronan synthases alters vascular smooth muscle cell phenotype and promotes monocyte adhesion. J Cell Physiol 2006, 206:378-385.
121. Xing R., Regezi J.A., Stern M., Shuster S., Stern R. Hyaluronan and CD44 expression in minor salivary gland tumors. Oral Dis 1998, 4:241-247.
122. Yabushita H., Kishida T., Fusano K., et al. Role of hyaluronan and hyaluronan synthase in endometrial cancer. Oncol Rep 2005, 13:1101-1105.
123. Yabushita H., Noguchi M., Kishida T., et al. Hyaluronan synthase expression in ovarian cancer. Oncol Rep 2004, 12:739-743.
124. Yamada Y., Itano N., Narimatsu H., et al. Elevated transcript level of hyaluronan synthase1 gene correlates with poor prognosis of human colon cancer. Clin Exp Metastasis 2004, 21:57-63.
125. Zeng C., Toole B.P., Kinney S.D., Kuo J.W., Stamenkovic I. Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer 1998, 77:396-401.
126. Zhai Y., Hotary K.B., Nan B., et al. Expression of membrane type 1 matrix metalloproteinase is associated with cervical carcinoma progression and invasion. Cancer Res 2005, 65:6543-6550.
127. Zoltan-Jones A., Huang L., Ghatak S., Toole B.P. Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells. J Biol Chem 2003, 278:45801-45810.